Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Liver Cirrhosis

  Free Subscription


Articles published in J Gastroenterol

Retrieve available abstracts of 39 articles:
HTML format
Text format



Single Articles


    November 2019
  1. ENOMOTO H, Ueno Y, Hiasa Y, Nishikawa H, et al
    Transition in the etiology of liver cirrhosis in Japan: a nationwide survey.
    J Gastroenterol. 2019 Nov 25. pii: 10.1007/s00535-019-01645.
    PubMed     Text format     Abstract available


    September 2019
  2. PUIGVEHI M, Londono MC, Torras X, Lorente S, et al
    Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients.
    J Gastroenterol. 2019 Sep 6. pii: 10.1007/s00535-019-01619.
    PubMed     Text format     Abstract available


  3. NAMBA M, Hiramatsu A, Aikata H, Kodama K, et al
    Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.
    J Gastroenterol. 2019 Sep 4. pii: 10.1007/s00535-019-01623.
    PubMed     Text format     Abstract available


    August 2019
  4. EBADI M, Bhanji RA, Mazurak VC, Montano-Loza AJ, et al
    Sarcopenia in cirrhosis: from pathogenesis to interventions.
    J Gastroenterol. 2019 Aug 7. pii: 10.1007/s00535-019-01605.
    PubMed     Text format     Abstract available


    March 2019
  5. NAGANUMA A, Chayama K, Notsumata K, Gane E, et al
    Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
    J Gastroenterol. 2019 Mar 13. pii: 10.1007/s00535-019-01569.
    PubMed     Text format     Abstract available


    February 2019
  6. KIM SK, Takeda H, Takai A, Matsumoto T, et al
    Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis.
    J Gastroenterol. 2019 Feb 12. pii: 10.1007/s00535-019-01555.
    PubMed     Text format     Abstract available


  7. SHIRABE K, Bekki Y, Gantumur D, Araki K, et al
    Response to the letter by Dr. Naoya Yamada, and Dr. Koichi Mizuta regarding our manuscript: "Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis".
    J Gastroenterol. 2019;54:206-207.
    PubMed     Text format    


    January 2019
  8. KIMURA K
    Long-awaited treatment for hepatitis C virus decompensated cirrhosis.
    J Gastroenterol. 2019 Jan 1. pii: 10.1007/s00535-018-01538.
    PubMed     Text format    


    November 2018
  9. YAMADA N, Mizuta K
    Advanced assessment of serum Mac-2 binding protein glycosylation isomer in patients with biliary atresia.
    J Gastroenterol. 2018 Nov 9. pii: 10.1007/s00535-018-1523.
    PubMed     Text format    


    September 2018
  10. TAKEHARA T, Sakamoto N, Nishiguchi S, Ikeda F, et al
    Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
    J Gastroenterol. 2018 Sep 10. pii: 10.1007/s00535-018-1503.
    PubMed     Text format     Abstract available


    June 2018
  11. HUANG R, Wang J, Xia J, Hao Y, et al
    Potential clinical application of strain elastography in chronic liver diseases.
    J Gastroenterol. 2018;53:795-796.
    PubMed     Text format    


    April 2018
  12. KAKISAKA K, Suzuki Y, Fujiwara Y, Abe T, et al
    Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.
    J Gastroenterol. 2018 Apr 21. pii: 10.1007/s00535-018-1468.
    PubMed     Text format     Abstract available


  13. YAGI M, Tanaka A, Namisaki T, Takahashi A, et al
    Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.
    J Gastroenterol. 2018 Apr 16. pii: 10.1007/s00535-018-1465.
    PubMed     Text format     Abstract available


  14. TSUJI K, Kurosaki M, Itakura J, Mori N, et al
    Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    J Gastroenterol. 2018 Apr 6. pii: 10.1007/s00535-018-1455.
    PubMed     Text format     Abstract available


    March 2018
  15. AKUTA N, Toyota J, Karino Y, Ikeda F, et al
    Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
    J Gastroenterol. 2018 Mar 2. pii: 10.1007/s00535-018-1445.
    PubMed     Text format     Abstract available


    January 2018
  16. ZEUZEM S, Serfaty L, Vierling J, Cheng W, et al
    The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.
    J Gastroenterol. 2018 Jan 17. pii: 10.1007/s00535-018-1429.
    PubMed     Text format     Abstract available


    November 2017
  17. SUZUKI Y, Mori T, Yokoyama M, Kim S, et al
    A proposed severity classification system for hepatolithiasis based on an analysis of prognostic factors in a Japanese patient cohort.
    J Gastroenterol. 2017 Nov 8. doi: 10.1007/s00535-017-1410.
    PubMed     Text format     Abstract available


  18. SHANG L, Hosseini M, Liu X, Kisseleva T, et al
    Human hepatic stellate cell isolation and characterization.
    J Gastroenterol. 2017 Nov 1. doi: 10.1007/s00535-017-1404.
    PubMed     Text format     Abstract available


    September 2017
  19. CHAYAMA K, Suzuki F, Karino Y, Kawakami Y, et al
    Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
    J Gastroenterol. 2017 Sep 25. doi: 10.1007/s00535-017-1391.
    PubMed     Text format     Abstract available


    August 2017
  20. KOBAYASHI K, Maruyama H, Kiyono S, Ogasawara S, et al
    Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis.
    J Gastroenterol. 2017 Aug 18. doi: 10.1007/s00535-017-1378.
    PubMed     Text format     Abstract available


  21. SHIDA T, Akiyama K, Oh S, Sawai A, et al
    Skeletal muscle mass to visceral fat area ratio is an important determinant affecting hepatic conditions of non-alcoholic fatty liver disease.
    J Gastroenterol. 2017 Aug 8. doi: 10.1007/s00535-017-1377.
    PubMed     Text format     Abstract available


    July 2017
  22. KITAJIMA Y, Takahashi H, Akiyama T, Murayama K, et al
    Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis.
    J Gastroenterol. 2017 Jul 24. doi: 10.1007/s00535-017-1370.
    PubMed     Text format     Abstract available


    June 2017
  23. HIRAMINE Y, Uojima H, Nakanishi H, Hiramatsu A, et al
    Response criteria of tolvaptan for the treatment of hepatic edema.
    J Gastroenterol. 2017 Jun 29. doi: 10.1007/s00535-017-1366.
    PubMed     Text format     Abstract available


  24. OKANOUE T, Ebise H, Kai T, Mizuno M, et al
    A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis.
    J Gastroenterol. 2017 Jun 6. doi: 10.1007/s00535-017-1355.
    PubMed     Text format     Abstract available


  25. TAJIRI K, Kawai K, Sugiyama T
    Strain elastography for assessment of liver fibrosis and prognosis in patients with chronic liver diseases.
    J Gastroenterol. 2017;52:724-733.
    PubMed     Text format     Abstract available


    April 2017
  26. FLOREANI A, Tanaka A, Bowlus C, Gershwin ME, et al
    Geoepidemiology and changing mortality in primary biliary cholangitis.
    J Gastroenterol. 2017 Apr 1. doi: 10.1007/s00535-017-1333.
    PubMed     Text format     Abstract available


    February 2017
  27. SETO WK, Yuen MF
    Nonalcoholic fatty liver disease in Asia: emerging perspectives.
    J Gastroenterol. 2017;52:164-174.
    PubMed     Text format     Abstract available


    January 2017
  28. UTSUNOMIYA H, Yamamoto Y, Takeshita E, Tokumoto Y, et al
    Upregulated absorption of dietary palmitic acids with changes in intestinal transporters in non-alcoholic steatohepatitis (NASH).
    J Gastroenterol. 2017 Jan 6. doi: 10.1007/s00535-016-1298.
    PubMed     Text format     Abstract available


    December 2016
  29. WANG W, Pan Q, Fuhler GM, Smits R, et al
    Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.
    J Gastroenterol. 2016 Dec 29. doi: 10.1007/s00535-016-1299.
    PubMed     Text format     Abstract available


  30. OGAWA E, Furusyo N, Nomura H, Dohmen K, et al
    NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    November 2016
  31. SETOYAMA H, Tanaka M, Nagumo K, Naoe H, et al
    Oral branched-chain amino acid granules improve structure and function of human serum albumin in cirrhotic patients.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  32. KUMADA H, Suzuki Y, Karino Y, Chayama K, et al
    The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  33. TERAI S, Tsuchiya A
    Status of and candidates for cell therapy in liver cirrhosis: overcoming the "point of no return" in advanced liver cirrhosis.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  34. TOYOTA J, Karino Y, Suzuki F, Ikeda F, et al
    Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  35. YAMADA N, Sanada Y, Tashiro M, Hirata Y, et al
    Serum Mac-2 binding protein glycosylation isomer predicts grade F4 liver fibrosis in patients with biliary atresia.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    April 2016
  36. SUGIYAMA A, Kanno K, Nishimichi N, Ohta S, et al
    Periostin promotes hepatic fibrosis in mice by modulating hepatic stellate cell activation via alpha integrin interaction.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    September 2015
  37. TADA T, Kumada T, Toyoda H, Kiriyama S, et al
    Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  38. DEGIORGIO D, Crosignani A, Colombo C, Bordo D, et al
    ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    July 2015
  39. NAMISAKI T, Noguchi R, Moriya K, Kitade M, et al
    Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: